Jefferies Financial Group Brokers Reduce Earnings Estimates for Immatics (NASDAQ:IMTX)

Immatics (NASDAQ:IMTXGet Rating) – Investment analysts at Jefferies Financial Group lowered their FY2026 earnings per share (EPS) estimates for shares of Immatics in a research report issued to clients and investors on Thursday, November 17th. Jefferies Financial Group analyst K. Shi now anticipates that the company will post earnings per share of $1.10 for the year, down from their previous estimate of $1.26. The consensus estimate for Immatics’ current full-year earnings is $0.42 per share.

Separately, Chardan Capital dropped their price objective on Immatics from $30.00 to $28.00 and set a “buy” rating on the stock in a report on Wednesday, August 10th.

Immatics Stock Performance

Shares of NASDAQ:IMTX opened at $10.55 on Monday. The company has a market cap of $804.19 million, a P/E ratio of 15.75, a PEG ratio of 2.89 and a beta of 0.48. Immatics has a one year low of $5.75 and a one year high of $14.00. The business’s 50-day simple moving average is $10.50 and its 200 day simple moving average is $9.86.

Institutional Trading of Immatics

Institutional investors have recently modified their holdings of the company. BlackRock Inc. purchased a new stake in Immatics in the 1st quarter worth about $27,000. Wolverine Asset Management LLC purchased a new stake in Immatics in the 2nd quarter worth about $42,000. UBS Group AG increased its position in Immatics by 230.3% in the 2nd quarter. UBS Group AG now owns 5,862 shares of the company’s stock worth $51,000 after purchasing an additional 4,087 shares during the last quarter. Lazard Asset Management LLC purchased a new stake in shares of Immatics during the 1st quarter worth about $84,000. Finally, Trexquant Investment LP purchased a new stake in shares of Immatics during the 2nd quarter worth about $98,000. Institutional investors and hedge funds own 34.12% of the company’s stock.

About Immatics

(Get Rating)

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.

Featured Articles

Earnings History and Estimates for Immatics (NASDAQ:IMTX)

Receive News & Ratings for Immatics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immatics and related companies with's FREE daily email newsletter.